BERN - The department said on Tuesday that makers keep altering the chemical structure of synthetic drugs, so a new variant reaches shops under a new name. There are no reliable findings on the effects, toxicity, dependence risk or interactions of these substances. Because they resemble drugs that are already controlled, the department said significant health risks have to be assumed.
What list e now covers
The change sits in annex 6 of the narcotics directory ordinance, the list of raw materials and products with a suspected narcotic-like effect. Swissmedic asked for the update. The medicines agency watches new synthetic substances with Swiss and foreign partners and looks for signs they are being misused. This round adds two individual substances and one group built around synthetic cannabinoids. Industrial use and scientific use stay exempt. Private use does not.
List e has been extended at regular intervals since December 2011. With this round it contains 323 individual substances and substance groups. The department said the aim is to bring new psychoactive substances under control early, to limit how far they spread, and to stop Switzerland becoming a trading place for designer drugs. The Federal Council adopted the ordinance amendment on 12 October. It was published in the official compilation this week and applies from 10 November.
A longer list inside the existing law
The Narcotics Act already makes manufacture, trade and use of a controlled substance illegal. Tuesday's step decides which new molecules fall inside that ban, so a small change in a formula does not produce a product that sits outside the list. It is the same method Bern has used for more than a decade: widen the directory when a new family of substances shows up, and leave the criminal law where parliament put it.
The health argument is the one the department put in its release. Buyers cannot judge the risk, and the state will not wait for a full toxicology file before it closes the trade. People looking for care, as opposed to a legal classification, meet a different part of the same system. This week RTS set out how far Swiss insurers diverge when a cancer drug is prescribed outside its official label.
